Optimal Management Strategies for Reducing the Cardiovascular Risk in Patients with Hypertriglyceridemia

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Amarin Pharma

Description:
Hypertriglyceridemia refers to a condition in which patients have high levels of triglycerides, which is the most abundant fatty molecule in the bloodstream of most organisms. Triglyceride levels provide important information as a marker associated with the risk for heart disease and stroke, particularly in the setting of low high-density lipoprotein (HDL) cholesterol levels and/or elevated low-density lipoprotein (LDL) cholesterol levels. The main treatment focus of hypertriglyceridemia is by restriction of carbohydrates and fat in the diet and reducing the risk of cardiovascular events through lipid management, and statin therapy has the potential to reduce the risks associated with cardiovascular disease (CVD). The greater the baseline level of triglycerides the greater the percent triglyceride reduction will be with statin treatment. In addition to statin treatment, 3 classes of medications are appropriate for the management of major triglyceride elevations and they include fibric acid derivatives, niacin, and omega-3 fatty acids. Recent clinical trials have shown that omega-3 fatty acids have the ability to lower CV risk in patients with high triglycerides and mixed dyslipidemia. Continued studies have shown that icosapent ethyl capsules, which are the latest addition to the omega 3 fatty acid treatment regimen, have demonstrated the ability to reduce triglyceride levels without elevation in levels of LDL-C.

Upon completion of this activity, participants will be able to:

  • Analyze the current guideline recommendations supporting the role of elevated triglycerides as a risk factor for cardiovascular disease (CVD)

  • Examine the latest data on the safety and efficacy of omega-3 fatty acids and their role in reducing cardiovascular risk

  • Assess different multidisciplinary strategies to effectively treat hypertriglyceridemia in patients at risk for CVD

  • Identify optimal management strategies to select patients who would benefit from omega-3 fatty acid treatment to reduce cardiovascular risk

  • Describe the challenges for current and emerging treatments and how to manage adherence and adverse events associated with them
     

Faculty: Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine

Disclosure:

Dr. Miller serves on an advisory board for Amarin. He was also on the steering committee for the REDUCE-IT clinical trial. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Amarin Pharma

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue